risankizumab   Click here for help

GtoPdb Ligand ID: 8922

Synonyms: ABBV-066 | BI 655066 | BI-655066 | risankizumab-rzaa | Skyrizi®
Approved drug Immunopharmacology Ligand
risankizumab is an approved drug (Japan, FDA & EMA (2019))
Compound class: Antibody
Comment: Risankizumab (research code BI 655066) is a humanised monoclonal antibody targeting interleukin 23A (IL-23A) [11]. It was developed through collaboration between Boehringer Ingelheim and AbbVie for the treatment of autoinflammatory diseases.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
Immunopharmacology Comments
Risankizumab is the second anti-IL-23A biologic therapy to receive clinical approval, following authorisation of tildrakizumab in 2018 (EMA and FDA).
The IL-23/IL-17 axis plays an important role in the development of chronic inflammation [7], with potential genetic links between the IL-23 receptor (IL-23R) or its ligand identified in inflammatory diseases including psoriasis and inflammatory bowel disease [10]. Risankizumab blocks this signalling pathway to mediate its immunomodulatory benefit.
Risankizumab is reported to exhibit higher efficacy than the anti-anti-IL-12/23p40 monoclonal ustekinumab in Phase 3 evaluation in patients with moderate to severe chronic plaque psoriasis [1,8]. The adverse event profiles of both drugs are comparable.
Immunopharmacology Disease
Disease X-Refs Comment References
Asthma Disease Ontology: DOID:2841
OMIM: 600807
Phase 2 clinical candidate for asthma (see NCT02443298).
Crohn's disease Disease Ontology: DOID:8778
OMIM: 266600
Orphanet: ORPHA206
Phase 3 clinical candidate for CD (see NCT03105102).
Ankylosing spondylitis Disease Ontology: DOID:7147
Phase 2 proof of concept trial in ankylosing spondylitis has been completed.
Psoriasis Disease Ontology: DOID:8893
Approved therapy for moderate to severe psoriasis (FDA April 2019).